{
    "organizations": [],
    "uuid": "ffba9070509640fafa7018a84a81494eeb26c931",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fibrocell-announces-review-of-stra/brief-fibrocell-announces-review-of-strategic-alternatives-idUSASC09W9X",
    "ord_in_thread": 0,
    "title": "BRIEF-Fibrocell Announces Review Of Strategic Alternatives",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 18 (Reuters) - Fibrocell Science Inc:\n* FIBROCELL ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES * FIBROCELL SCIENCE INC - HAS ENGAGED CANACCORD GENUITY LLC AS ITS STRATEGIC FINANCIAL ADVISOR TO ASSIST WITH THIS REVIEW PROCESS\n* FIBROCELL - POTENTIAL STRATEGIC ALTERNATIVES MAY INCLUDE SALE OF CO, BUSINESS COMBINATION, MERGER OR REVERSE MERGER WITH ANOTHER CO\n* FIBROCELL - POTENTIAL STRATEGIC ALTERNATIVES MAY INCLUDE STRATEGIC INVESTMENT INTO CO, SALE, LICENSE OR OTHER DISPOSITION OF CORPORATE ASSETS\n* FIBROCELL - POTENTIAL STRATEGIC ALTERNATIVES MAY INCLUDE CONTINUING WITH CURRENT BUSINESS PLAN\n* FIBROCELL SCIENCE INC - IN STRATEGIC REVIEW, BOARD IS CONSIDERING FIBROCELLâ€™S CLINICAL PROGRAMS FOR RARE SKIN DISEASES WITH UNMET NEEDS AMONG OTHERS\n* FIBROCELL SCIENCE - INTENDS TO CONTINUE ADVANCING PHASE 1/2 CLINICAL TRIAL OF FCX-007 AND PROVIDE A TRIAL UPDATE IN Q2 OF 2018\n* FIBROCELL - BELIEVES CASH AND CASH EQUIVALENTS AS OF MARCH 31 WILL BE SUFFICIENT TO FUND OPERATIONS INTO Q1 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-18T20:20:00.000+03:00",
    "crawled": "2018-04-19T14:52:49.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "fibrocell",
        "science",
        "inc",
        "fibrocell",
        "announces",
        "review",
        "strategic",
        "alternative",
        "fibrocell",
        "science",
        "inc",
        "engaged",
        "canaccord",
        "genuity",
        "llc",
        "strategic",
        "financial",
        "advisor",
        "assist",
        "review",
        "process",
        "fibrocell",
        "potential",
        "strategic",
        "alternative",
        "may",
        "include",
        "sale",
        "co",
        "business",
        "combination",
        "merger",
        "reverse",
        "merger",
        "another",
        "co",
        "fibrocell",
        "potential",
        "strategic",
        "alternative",
        "may",
        "include",
        "strategic",
        "investment",
        "co",
        "sale",
        "license",
        "disposition",
        "corporate",
        "asset",
        "fibrocell",
        "potential",
        "strategic",
        "alternative",
        "may",
        "include",
        "continuing",
        "current",
        "business",
        "plan",
        "fibrocell",
        "science",
        "inc",
        "strategic",
        "review",
        "board",
        "considering",
        "fibrocell",
        "clinical",
        "program",
        "rare",
        "skin",
        "disease",
        "unmet",
        "need",
        "among",
        "others",
        "fibrocell",
        "science",
        "intends",
        "continue",
        "advancing",
        "phase",
        "clinical",
        "trial",
        "provide",
        "trial",
        "update",
        "q2",
        "fibrocell",
        "belief",
        "cash",
        "cash",
        "equivalent",
        "march",
        "sufficient",
        "fund",
        "operation",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}